* India Formulations: The formulations segment generated revenue of INR 13,758 mn, reflecting a 12% YoY growth, primarily driven by strong volume growth in pillar brands and innovative products, contributing 22.8% to total sales. The company launched 10 new products, including 3 first-in-India launches, and outpaced the IPM in key therapies such as Cardiology, Gynecology, Dermatology, Respiratory, Antiinfectives, and super-specialty areas like Oncology and Nephrology. The company maintained i...
Buy Zydus Lifesciences Ltd For Target Rs. 1,319 By Choice Broking Ltd
